皮膚真菌症の世界市場レポート 2025年

皮膚真菌症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で185億9,000万米ドルに成長します。予測期間中に予想される成長の原動力は、高齢化人口の増加、薬剤耐性真菌の増加、天然・有機抗真菌製品に対する需要の高まり、バイオテクノロジーと抗真菌研究の進歩、発展途上地域におけるヘルスケアアクセスの改善などの要因です。この期間に予想される主要動向としては、新しい抗真菌薬の開発、迅速診断法の進歩、皮膚科学における人工知能の統合、ナノテクノロジーを利用した抗真菌治療法の発展、微生物ベースの治療法の革新などが挙げられます。

真菌感染症の有病率の増加は、今後数年間の皮膚真菌症市場の成長を促進すると予想されます。真菌感染症は、真菌が皮膚、爪、毛髪、内臓などに感染することで発症し、さまざまな健康合併症を引き起こします。広域抗生物質の過剰使用は、自然のマイクロバイオームを破壊し、真菌が繁殖して感染症を引き起こす環境を作り出します。このような混乱は、身体の自然な防御機構を弱め、日和見真菌感染症にかかりやすくします。皮膚真菌症皮膚糸状菌、酵母、カビによって引き起こされる真菌症は、さまざまな組織に影響を及ぼし、表面感染と全身感染の両方を引き起こします。例えば、2023年11月、英国の公衆衛生機関であるUK Health Security Agencyは、世界の推定では年間650万人の侵襲性真菌感染症が発生し、約380万人が死亡し、250万人がこれらの感染症に直接起因していると報告しています。その結果、真菌感染症の有病率の上昇が皮膚真菌症市場の成長を促進しています。

経口薬への需要の高まりが、今後の皮膚真菌症市場の拡大に寄与すると予測されています。経口薬とは、錠剤、カプセル剤、液剤などの形態で口から服用する薬剤のことで、消化器官から吸収されます。注射や他のデリバリー方法に比べて利便性が高く、効果も高いため、経口薬が様々な疾患の治療選択肢として好まれるようになってきています。皮膚真菌症治療の利点は、全身性の抗真菌剤が血液循環を通じて感染した皮膚、毛髪、爪に浸透し、外用薬に比べてより深く、より長く治療が持続することです。例えば、2022年10月、米国の政府機関である疾病対策予防センターは、経口抗ウイルス剤の調剤数が57％増加し、2022年4月24日から5月21日の間に10万人当たり643人であったものが、2022年7月31日から8月28日の間に10万人当たり1,012人に増加したと報告しています。その結果、経口薬に対する需要の高まりが皮膚真菌症市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の皮膚真菌症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の皮膚真菌症市場：成長率分析
• 世界の皮膚真菌症市場の実績：規模と成長、2019～2024年
• 世界の皮膚真菌症市場の予測：規模と成長、2024～2029年、2034年
• 世界の皮膚真菌症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の皮膚真菌症市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• コルチコステロイド節約薬
• 免疫抑制剤
• 免疫調節剤
• 抗真菌薬
• その他
• 世界の皮膚真菌症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 局所
• その他
• 世界の皮膚真菌症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• その他
• 世界の皮膚真菌症市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所コルチコステロイド
• 経口コルチコステロイド
• 注射用コルチコステロイド
• 世界の皮膚真菌症市場、コルチコステロイド節約薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• タクロリムス
• ピメクロリムス
• 世界の皮膚真菌症市場、免疫抑制剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• メトトレキサート
• アザチオプリン
• シクロホスファミド
• 世界の皮膚真菌症市場、免疫調節剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インターフェロン-ガンマ
• サリドマイド
• 世界の皮膚真菌症市場、抗真菌剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所抗真菌薬
• 経口抗真菌薬
• 全身性抗真菌薬
• 世界の皮膚真菌症市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗ヒスタミン薬
• 抗菌剤

第7章 地域別・国別分析

• 世界の皮膚真菌症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の皮膚真菌症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 皮膚真菌症市場：競合情勢
• 皮膚真菌症市場：企業プロファイル
  • Pfizer Inc.
  • Bayer AG
  • Saphnix Life Sciences
  • MITS Healthcare Private Limited
  • Weefsel Pharma

第31章 その他の大手企業と革新的企業

• AdvaCare Pharma
• Associated BIoTech
• Healthy Life Pharma Private Limited
• Blueberry Therapeutics Ltd.
• Livealth Biopharma Pvt. Ltd.
• LGM Pharma
• SiNi Pharma Pvt. Ltd.
• Joshi Agrochem Pharma Private Limited
• Wellona Pharma
• Abiba Pharmacia Pvt. Ltd.
• Vee Excel Drugs & Pharmaceuticals Pvt. Ltd.
• Femcorp Pharma
• Lexicare Pharma Pvt. Ltd.
• Glamris Dermacare
• Henin Lukinz

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 皮膚真菌症市場、2029年：新たな機会を提供する国
• 皮膚真菌症市場、2029年：新たな機会を提供するセグメント
• 皮膚真菌症市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Dermatomycoses refer to a group of fungal infections that affect the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often result in symptoms such as itching, scaling, redness, and skin inflammation, negatively impacting skin health. The primary aim of treatment is to eradicate the fungal infection, relieve symptoms, and prevent recurrence through the use of antifungal medications, proper hygiene, and consistent skin care practices.

The main drug categories for treating dermatomycoses include corticosteroids, corticosteroid-sparing agents, immunosuppressives, immunomodulators, antifungals, and others. Corticosteroids are anti-inflammatory drugs that help reduce swelling, redness, and itching in skin conditions. These medications can be administered in various forms, such as oral, parenteral, topical, and others, and are used by different end-users, including hospitals, specialty clinics, and others.

The dermatomycoses market research report is one of a series of new reports from The Business Research Company that provides dermatomycoses market statistics, including the dermatomycoses industry global market size, regional shares, competitors with the dermatomycoses market share, detailed dermatomycoses market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomycoses industry. This dermatomycoses market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatomycoses market size has grown strongly in recent years. It will grow from $14.12 billion in 2024 to $14.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to advancements in antifungal therapies, the rising prevalence of fungal infections, growing awareness about skin health, improvements in diagnostic techniques, and the expansion of over-the-counter antifungal products.

The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $18.59 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth during the forecast period is driven by factors such as the rising aging population, the increasing prevalence of drug-resistant fungal strains, the growing demand for natural and organic antifungal products, advancements in biotechnology and antifungal research, and improved healthcare access in developing regions. Key trends expected in this period include the development of new antifungal drugs, progress in rapid diagnostic methods, the integration of artificial intelligence in dermatology, advancements in nanotechnology-based antifungal treatments, and innovations in microbiome-based therapies.

The increasing prevalence of fungal infections is expected to drive the growth of the dermatomycoses market in the coming years. Fungal infections occur when fungi infect the skin, nails, hair, or internal organs, leading to various health complications. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, creating an environment that allows fungi to thrive and cause infections. This disruption weakens the body's natural defense mechanisms, making individuals more susceptible to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, are responsible for fungal diseases, affecting different tissues and leading to both superficial and systemic infections. For example, in November 2023, the UK Health Security Agency, a UK-based public health organization, reported that global estimates indicate an annual occurrence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 million directly attributed to these infections. As a result, the rising prevalence of fungal infections is fueling the growth of the dermatomycoses market.

The increasing demand for oral drugs is anticipated to contribute to the expansion of the dermatomycoses market in the future. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The preference for oral drugs is growing as they offer greater convenience and effectiveness compared to injections or other delivery methods, making them a favored treatment option for various conditions. Dermatomycoses treatment benefits from oral drugs by enabling systemic antifungal agents to penetrate infected skin, hair, or nails through blood circulation, ensuring deeper and longer-lasting treatment compared to topical applications. For example, in October 2022, the Centers for Disease Control and Prevention, a US-based government agency, reported a 57% increase in oral antiviral dispensing, rising from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Consequently, the growing demand for oral drugs is driving the dermatomycoses market forward.

Leading companies in the dermatomycoses market are concentrating on investigational new drug candidates to enhance onychomycosis treatment and improve therapeutic efficacy. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical trials to assess its safety, effectiveness, and potential for regulatory approval before becoming an authorized treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its investigational new drug VTR-297, intended for the treatment of onychomycosis. VTR-297 is distinguished by its histone deacetylase (HDAC) inhibitor properties, setting it apart from conventional antifungal treatments. This approach targets the root cause of fungal growth, exhibiting strong antifungal activity against dermatophytes and other fungi. The novel mechanism of action has the potential to deliver faster and more effective treatment outcomes while reducing the risk of infection recurrence, addressing a critical unmet need in onychomycosis treatment.

Major players in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz.

North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycoses report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatomycoses market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatomycoses market consists of sales of barrier creams or protective skin creams, medicated soaps and body washes, and cryotherapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatomycoses Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dermatomycoses market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dermatomycoses ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomycoses market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Corticosteroids; Corticosteroid-Sparing Agents; Immunosuppressive; Immunomodulator; Antifungals; Other Drugs
• 2) By Route Of Administration: Oral; Parenteral; Topical; Other Routes Of Administration
• 3) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Sub Segments:
• 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
• 2) By Corticosteroid-Sparing Agents: Tacrolimus; Pimecrolimus
• 3) By Immunosuppressive: Methotrexate; Azathioprine; Cyclophosphamide
• 4) By Immunomodulator: Interferon-Gamma; Thalidomide
• 5) By Antifungals: Topical Antifungals; Oral Antifungals; Systemic Antifungals
• 6) By Other Drugs: Antihistamines; Antibacterial Agents
• Companies Mentioned: Pfizer Inc.; Bayer AG; Saphnix Life Sciences; MITS Healthcare Private Limited; Weefsel Pharma
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dermatomycoses Market Characteristics

3. Dermatomycoses Market Trends And Strategies

4. Dermatomycoses Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dermatomycoses Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dermatomycoses PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dermatomycoses Market Growth Rate Analysis
• 5.4. Global Dermatomycoses Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dermatomycoses Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dermatomycoses Total Addressable Market (TAM)

6. Dermatomycoses Market Segmentation

• 6.1. Global Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Corticosteroid-Sparing Agents
• Immunosuppressive
• Immunomodulator
• Antifungals
• Other Drugs
• 6.2. Global Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• Other Routes Of Administration
• 6.3. Global Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.4. Global Dermatomycoses Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Oral Corticosteroids
• Injectable Corticosteroids
• 6.5. Global Dermatomycoses Market, Sub-Segmentation Of Corticosteroid-Sparing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tacrolimus
• Pimecrolimus
• 6.6. Global Dermatomycoses Market, Sub-Segmentation Of Immunosuppressive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Azathioprine
• Cyclophosphamide
• 6.7. Global Dermatomycoses Market, Sub-Segmentation Of Immunomodulator, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon-Gamma
• Thalidomide
• 6.8. Global Dermatomycoses Market, Sub-Segmentation Of Antifungals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antifungals
• Oral Antifungals
• Systemic Antifungals
• 6.9. Global Dermatomycoses Market, Sub-Segmentation Of Other Drugs, By Tyepe, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamines
• Antibacterial Agents

7. Dermatomycoses Market Regional And Country Analysis

• 7.1. Global Dermatomycoses Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dermatomycoses Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dermatomycoses Market

• 8.1. Asia-Pacific Dermatomycoses Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dermatomycoses Market

• 9.1. China Dermatomycoses Market Overview
• 9.2. China Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dermatomycoses Market

• 10.1. India Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dermatomycoses Market

• 11.1. Japan Dermatomycoses Market Overview
• 11.2. Japan Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dermatomycoses Market

• 12.1. Australia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dermatomycoses Market

• 13.1. Indonesia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dermatomycoses Market

• 14.1. South Korea Dermatomycoses Market Overview
• 14.2. South Korea Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dermatomycoses Market

• 15.1. Western Europe Dermatomycoses Market Overview
• 15.2. Western Europe Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dermatomycoses Market

• 16.1. UK Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dermatomycoses Market

• 17.1. Germany Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dermatomycoses Market

• 18.1. France Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dermatomycoses Market

• 19.1. Italy Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dermatomycoses Market

• 20.1. Spain Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dermatomycoses Market

• 21.1. Eastern Europe Dermatomycoses Market Overview
• 21.2. Eastern Europe Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dermatomycoses Market

• 22.1. Russia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dermatomycoses Market

• 23.1. North America Dermatomycoses Market Overview
• 23.2. North America Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dermatomycoses Market

• 24.1. USA Dermatomycoses Market Overview
• 24.2. USA Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dermatomycoses Market

• 25.1. Canada Dermatomycoses Market Overview
• 25.2. Canada Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dermatomycoses Market

• 26.1. South America Dermatomycoses Market Overview
• 26.2. South America Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dermatomycoses Market

• 27.1. Brazil Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dermatomycoses Market

• 28.1. Middle East Dermatomycoses Market Overview
• 28.2. Middle East Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dermatomycoses Market

• 29.1. Africa Dermatomycoses Market Overview
• 29.2. Africa Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dermatomycoses Market Competitive Landscape And Company Profiles

• 30.1. Dermatomycoses Market Competitive Landscape
• 30.2. Dermatomycoses Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Saphnix Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. MITS Healthcare Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Weefsel Pharma Overview, Products and Services, Strategy and Financial Analysis

31. Dermatomycoses Market Other Major And Innovative Companies

• 31.1. AdvaCare Pharma
• 31.2. Associated Biotech
• 31.3. Healthy Life Pharma Private Limited
• 31.4. Blueberry Therapeutics Ltd.
• 31.5. Livealth Biopharma Pvt. Ltd.
• 31.6. LGM Pharma
• 31.7. SiNi Pharma Pvt. Ltd.
• 31.8. Joshi Agrochem Pharma Private Limited
• 31.9. Wellona Pharma
• 31.10. Abiba Pharmacia Pvt. Ltd.
• 31.11. Vee Excel Drugs & Pharmaceuticals Pvt. Ltd.
• 31.12. Femcorp Pharma
• 31.13. Lexicare Pharma Pvt. Ltd.
• 31.14. Glamris Dermacare
• 31.15. Henin Lukinz

32. Global Dermatomycoses Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dermatomycoses Market

34. Recent Developments In The Dermatomycoses Market

35. Dermatomycoses Market High Potential Countries, Segments and Strategies

• 35.1 Dermatomycoses Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dermatomycoses Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dermatomycoses Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer